Impact Factor 2018: 1.772 (@Clarivate Analytics)
5-Year Impact Factor: 1.772 (@Clarivate Analytics)
  • Users Online: 278
  • Print this page
  • Email this page


 
 
Table of Contents
ORIGINAL ARTICLE
Year : 2019  |  Volume : 12  |  Issue : 6  |  Page : 283-287

Optimized combinations of statins and azoles against Acanthamoeba trophozoites and cysts in vitro


1 University Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain; Laboratoire Matériaux-Molécules et Applications, IPEST, LA Marsa, University of Carthage, Tunisia
2 University Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
3 Centre for Integrative Physiology, Biomedical Sciences, Edinburgh Medical School, University of Edinburgh, Scotland, UK

Date of Submission13-Nov-2018
Date of Decision13-May-2019
Date of Acceptance10-Jun-2019
Date of Web Publication27-Jun-2019

Correspondence Address:
José E Piñero
University Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands
Spain
Login to access the Email id

Source of Support: This work was supported by the grants Red de Investigation Colaborativa en Enfermedades Tropicales RICET (project no. RD16/0027/0001 of the programme of Redes Temáticas de Investigación Cooperativa, FIS), Spanish Ministry of Health, Madrid, Spain and PI13/00490 “Protozoosis Emergentes por Amebas de Vida Libre: Aislamiento, Caracterización, Nuevas Aproximaciones Terapéuticas y Traslación Clínica de los Resultados” from the Instituto de Salud Carlos III. IS and ALA were supported by the Agustín de Betancourt Programme. JEP was supported by Ayudas Plan Propio de la Universidad de La Laguna 2018 (proyectos puente I+D+i), Conflict of Interest: None


DOI: 10.4103/1995-7645.261287

Get Permissions

  Abstract 

Objective: To evaluate the combination of several statins (atorvastatin, fluvastatin and simvastatin) and azoles (voriconazole, posaconazole and itraconazole) against Acanthamoeba spp.
Methods: The efficiency of the different drug combinations against the trophozoite stage of different Acanthamoeba strains were evaluated by Alamar Blue assay. Effect on the cyst stage was observed by inverted microscope. Cytotoxicity of combinations of azoles and statins was evaluated by measuring the release of lactate dehydrogenase from a murine macrophage cell line.
Results: Combinations of any of the tested statins and voriconazole or posaconazole were more efficient in inhibiting Acanthamoeba compared to statins or azoles individually. The drug combinations at the combined inhibitory concentrations 50% showed lower toxicity compared to that of the compounds alone.
Conclusions: The combinations of statins together with voriconazole and posaconazole are more efficient than these drugs alone, and these combinations have lower cytotoxicity in mammalian cell lines.

Keywords: Keratitis, Voriconazole, Posaconazole, Atorvastatin, Fluvastatin, Simvastatin


How to cite this article:
Sifaoui I, Martín-Navarro CM, López-Arencibia A, Reyes-Batlle M, Valladares B, Piñero JE, Maciver SK, Lorenzo-Morales J. Optimized combinations of statins and azoles against Acanthamoeba trophozoites and cysts in vitro. Asian Pac J Trop Med 2019;12:283-7

How to cite this URL:
Sifaoui I, Martín-Navarro CM, López-Arencibia A, Reyes-Batlle M, Valladares B, Piñero JE, Maciver SK, Lorenzo-Morales J. Optimized combinations of statins and azoles against Acanthamoeba trophozoites and cysts in vitro. Asian Pac J Trop Med [serial online] 2019 [cited 2019 Jul 22];12:283-7. Available from: http://www.apjtm.org/text.asp?2019/12/6/283/261287




  1. Introduction Top


Among several genera of free-living Amoebae, Acanthamoeba genus are responsible for different diseases such as Acanthamoeba keratitis, a sight-threating ulceration of the cornea, granulomatous amoebic encephalitis and various disseminated infections (mostly cutaneous)[1],[2]. Current therapy against Acanthamoeba keratitis is based on topical applications of antimicrobials including various combinations of propamidine isethionate and neomycin or biguanides[1],[2]. However, Acanthamoeba can form a double wall cyst stage, which is highly resistant to external agents including those mentioned above that significantly complicates therapy[3].

This means that there is an urgent to discover drugs and drug regimens that are active against both trophozoites and cysts of Acanthamoeba[1],[2],[4],[5],[6].

Statins are hypolipidemic agents widely used to lower the cholesterol levels and to prevent atherosclerotic cardiovascular disease[7]. Our previous studies have also demonstrated the in vitro efficacy of statins against Acanthamoeba trophozoites and cysts, indicating them as a novel effective therapeutic approach against these pathogens[5]. Another agent which has shown high activity against both trophozoites and cysts of Acanthamoeba is voriconazole[6],[8]. Voriconazole belongs to the triazole family which has been shown to inhibit 14-a-demethylase resulting in the reduced production of ergsoterol in Acanthamoeba[9]. Ergosterol and 7-dehyrostigmasterol have been reported as the major sterols presented in Acanthamoeba[10],[11]. The high efficacy of voriconazole against Acanthamoeba strains in vitro and in clinical cases has been reported in previous studies[6],[8],[l2]. Other members of the family of triazoles that have been used as antifungals are posaconazole and itraconazole. Posaconazole has been previously reported to have a wide microbial activity spectrum and has recently been evaluated against Acanthamoeba cysts in vitro[9],[13]. Although itraconazole has been included in successful treatment combinations against skin lesions caused by Acanthamoeba, it is reported to be less active compared to other azoles[3],[l4]. In many cases, combinations of therapeutic drugs are found to be more efficient than the individually applied drugs. In the case of Acanthamoeba, this phenomenon has been demonstrated recently using combination of biguanides[4].

Although the activity of statins and triazoles has been already described against Acanthamoeba strains, they have not been tested in combination. In the present study, combinations of these molecules were tested for their amoebicidal and cysticidal activity as well as for their cytotoxicity in a mammalian cell line. We report that these drugs are more efficient in combination, which suggests a better approach for the treatment of Acanthamoeba infections.


  2. Materials and methods Top


2.1. Acanthamoeba strains

We have used 3 Acanthamoeba isolates in this study. One type strain Acanthamoeba castellami Neff (ATCC 30010, genotype T4) and 2 clinical strains previously isolated by our group CLC-16 (genotype T3), and CLC-51. l (genotype T1)[15]. All strains were cultured axenically at room temperature in Peptone Yeast Extract Glucose Broth (PYG) medium supplemented with 40 μg/mL gentamicin (Sigma-Aldrich Chemistry Ltd., Madrid, Spain).

2.2. Chemicals

Posaconazole and voriconazole were purchased from Sigma-Aldrich Chemistry Ltd. (Madrid, Spain) and itraconazole was purchased from the Cayman Chemical Company (Vitro, Madrid, Spain). Simvastatin, atorvastatin, and fluvastatin were purchased from the Cayman Chemical Company (Ann Arbor, MI, US).

2.3. Activity assays

The anti-Acanthamoeba activities of the drugs were determined by the AlamarBlue® assay, as previously described[15],[l6]. Briefly, 50 ņL of Acanthamoeba trophozoite cells (104 cells/mL) were seeded in 96-well microtiter plates. Amoebae were allowed to adhere for 15 min and 50 ņL of different dilutions of the drugs. Finally, 10 ņL of the Alamar Blue Assay Reagent (Bioresource, Europe, Nivelles, Belgium) to each well. Plates were then incubated for 120 h at 28 °C with slight agitation and were measured using an EnSpire® Multimode Plate Reader (Perkin Elmer, Madrid, Spain). A test wavelength of 570 nm and a reference wavelength of 630 nm were used. Inhibitory concentration 50% (IC50) and inhibitory concentration 90% (IC90) were calculated by non-linear regression analysis with 95% confidence limits. The IC50s of each drug alone were calculated and drug combinations were then tested at various concentration to determine the lowest IC50s of each drug combination.

2.4. Evaluation of the cysticidal activity of posaconazole

The effects of posaconazole against cysts were evaluated against the 3 strains of Acanthamoeba. Mature cysts were prepared as previously described[17]. Briefly, trophozoites were transferred from PYG medium to Neff’s encystment medium where they were cultured for a week under slight agitation to obtain mature cysts.

After that, the cells were harvested and washed twice with PYG medium. A concentration of 104 cysts/mL was transferred to plates containing fresh PYG medium and incubated with posaconazole at the previously calculated IC50s and IC90s. During a week, the number of trophozoites, cysts, and non-viable were counted in a Neubauer counting chamber each 24 h, as previously described by Martín- Navarro et al[5],[6]. A negative control including only mature cysts in Neff’s encystment medium was included to the experiments. After 7 d of incubation, the supernatant was replaced with fresh PYG medium and the cultures were observed for a second week to confirm the cysticidal activity.

2.5. Cytotoxicity evaluation

The murine macrophages cell line (ATCC TIB-67) was used to measure the cytotoxicity of the drugs individually and in combinations. This assay was evaluated by the measure of the release of lactate dehydrogenase by cytotoxicity detection kit (Roche Applied Science, Barcelona, Spain) according to the manufacturer’s instructions. Cytotoxicity less than 10% was considered as being non-cytotoxic, levels between 10%-25%, low toxicity, levels between 25%-40%, medium toxicity and higher than 40%, highly cytotoxic. The results were compared by one-way ANOVA using Sigma Plot 12.0 software (Systat Software Inc., London, UK)[2],[18].

2.6. Statistical analysis

All experiments were performed 3 times each in duplicate. Data were analysed using ANOVA, multiple post hoc analysis, Tukey’s test and a paired two-tailed t-test and P<0.05 were considered significant. Statistical analysis was done with the Sigma Plot 12.0 software program (Systat Software Inc., London, UK).


  3. Results Top


All of the 3 Acanthamoeba strains tested were found to be sensitive to the statins [Table 1], but the activity of itraconazole was low and this drug was not used in further experiments. All combinations of statins and voriconazole and posaconazole were active against the strains of Acanthamoeba. However, the different drugs combined, produced lower IC50s compared to that of the molecules alone [Table 2] and [Table 3].
Table 1: IC50 and IC90 values of posaconazole against different strains of Acanthamoeba measured by Alamar blue assay after 96 h (μM).

Click here to view
Table 2: IC50 values of atorvastatin, fluvastatin, simvastatin alone or in combination with voriconazole at a concentration corresponding to the IC50 for each of the three strains of Acanthamoeba after 96 h (μM).

Click here to view
Table 3: IC50 values of atorvastatin, fluvastatin, and simvastatin alone or in combination with posaconazole at a concentration corresponding to the IC50 for each of the three strains of Acanthamoeba after 96 h (mM).

Click here to view


The cysticidal activity of posaconazole was also evaluated and was found to reduce the viability of all 3 strains. The IC50 and IC90 of posaconazole for cysts was calculated [Figure 1]. No cysts was able to revert into trophozoites after 168 h.
Figure 1: Number of cysts when they were incubated with posaconazole with previously calculated IC50 and IC90 in PYG medium of Ac Neff (A), CLC- 16 (B) and CLC-51.l (C). Cysts were not viable after incubation with this drug, since amoebae were not able to excyst. Moreover, the number of cysts decreased with time and became non-viable cells.

Click here to view


Simvastatin IC50 (S50), posaconazole IC50 (P50), voriconazole IC50 (V50) and the following combinations of molecules: posaconazole and atorvastatin (P+A), posaconazole and fluvastatin (P+F), posaconazole and simvastatin (P+S), and voriconazole with atorvastatin, fluvastatin and simvastatin (V+A, V+F and V+S) did not induce cytotoxicity against macrophages. Whereas in the case of atorvastatin IC50 and IC90 (A50 and A90), fluvastatin IC50 and IC90 (F50 and F90), posaconazole IC90 (P90) and voriconazole IC90 (V90), low cytotoxicity values against macrophages were observed. Furthermore, moderate toxicity was shown in the case of cells incubated with simvastatin IC90 (S90). Amphotericin B IC90 (Amp B 90) and chlorhexidine IC90 (Chx90) induced high levels of toxicity in the tested cell line [Figure 2]. The statistical analysis revealed significant differences (P<0.001) in the cytotoxicity produced by the reference drugs (IC90 of Chx and AnfB) and all treatments, excepting in the comparison between Chx90 and S90 [Figure 2].
Figure 2: Cytotoxicity of atorvastatin (A), fluvastatin (F), simvastatin (S), posaconazole (P), voriconazole (V), amphotericin B (Amp B) and chlorhexidine (Chx) at IC50 and IC90 as well as the combination between azoles and statins produced in murine macrophages. S50, P50, V50 and the combinations of P+A, P+F, P+S, V+A, V+F and V+S were not cytotoxic against macrophages compared with the references drugs used; AmpB 90 and Chx90 showed high levels of cytotoxicity against macrophages. The cytotoxicity values showed significant differences with the cytotoxicity produced by chlorhexidine and amphotericin B. a-g: Different small letters represent statistically different results within the IC50 toxicity towards macrophages with P<0.05; A-F: Different capital letters represent statistically different results within the IC90 toxicity towards macrophages with P<0.05.

Click here to view



  4. Discussion Top


Drugs are often combined for their synergize activities to increase their therapeutic potency. There are many instances where this applies (e.g. HIV therapy) and this has also been found with Acanthamoeba, where polyhexamethylene biguanide combined effectively with chlorhexidine[4]. This has also been found with various other drug combinations[19]. It is also an advantage if the cytotoxicity produced by this combination will be the same or even lower than that produced by the individual drugs themselves. Such a decrease in the toxicity has been reported by the combination of PHMB and chlorhexidine on epithelial cells[4].

Statins and voriconazole were used in this study because of their proven amoebicidal and cysticidal activity and their relatively low cytotoxicity. The activity of atorvastatin, fluvastatin, simvastatin and voriconazole against Acanthamoeba was previously evaluated by our group[5],[6],[8],[16]. These in vitro results can be compared with in vivo experiment where voriconazole has been successfully used to treat amoebic infections, even against resistant Acanthamoeba strains[12]. Initially, those drugs were chosen because their molecular target, ergosterol was known to be a valid one. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an enzyme that catalyse the conversion of HMG-CoA to mevalonate, which is a precursor of cholesterol in vertebrates and ergosterol in fungi and some protozoa such as Acanthamoeba[5],[20]. Voriconazole is a triazole antifungal agent that causes demethylation of ergosterol. As both drugs act to inhibit different parts of the same ergosterol pathway, we suspected that these 2 drugs may be combined successfully.

Itraconazole has been included in some successful treatment regimens used against skin lesion in a lung transplant patient with disseminated acanthamoebiasis and against Acanthamoeba keratitis[14],[21]. However, resistance to azoles has been reported.

Acanthamoeba from skin nodules of a fatal cutaneous infection in an HIV patient, was resistant to a combination of drugs with itraconazole in vitro[21]. We confirmed that only a weakly amoebicidal effect of itraconazole, so it was discarded for further experiments. We could find only one study in which posaconazole has been used against Acanthamoeba, showed a cysticidal activity in clinical and culture collection isolates[9]. This previous study reported minimal cysticidal concentrations [(43.75-52.50) μM] that are higher than the IC50 found in the present study [(2.56-7.50) μM]. We have reported that statins and voriconazole lead to the death of Acanthamoeba by the activation of programmed cell death[8]. We have also reported that caffeine and maslinic acid also activate programmed cell death but we do not yet know the molecular targets of either drug. It remains to be seen if either caffeine or maslinic acid treatment will allow even lower concentrations of statins, posaconaole or voriconazole to be effective in human therapy[18].

The combination of statins together with voriconazole and posaconazole is more efficient than these drugs by themselves, and these combinations have lower cytotoxicity in mammalian cell lines. We anticipate that treatments based on combinations of statins and azoles will be more effective and better tolerated than present treatment regimens against Acanthamoeba infections of humans.

Conflict of interest statement

The authors declare no competing financial interests.

Foundation project

This work was supported by PI18/01380 from Instituto de Salud Carlos III and FEDER, Spain and CTQ2014-55888-C03-01/ R (MINECO). MRB: RICET [RD16/0027/0001 project, from Programa Redes Temáticas de Investigación Cooperativa, FIS (Ministerio Español de Salud, Madrid, Spain). IS and ALA were supported by the Agustín de Betancourt Programme.



 
  References Top

1.
Lorenzo-Morales J, Martín-Navarro CM, López-Arencibi A, Arnalich-Montiel F, Piñero JE, Valladares B. Acanthamoeba keratitis: An emerging disease gathering importance worldwide? Trends Parasitol 2013; 29(4): 181-187.  Back to cited text no. 1
    
2.
Lorenzo-Morales J, Martín-Navarro CM, López-Arencibia A, Santana-Morales MA, Afonso-Lehmann RN, Maciver SK, et al. Therapeutic potential of a combination of two gene-specific small interfering RNAs against clinical strains of Acanthamoeba. Antimicrob Agents Chemother 2010; 54(12): 5151-5155.  Back to cited text no. 2
    
3.
Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 2004; 34(9): 1001-1027  Back to cited text no. 3
    
4.
Mafra CSP, Carrijo-Carvalho LC, Chudzinski-Tavassi AM, de Carvalho Taguchi FM, Foronda AS, de Souza Carvalho FR, et al. Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity biguanides on Acanthamoeba cysts and cytotoxicity. Invest Ophthalmol Vis Sci 2013; 54(9): 6363-6372.  Back to cited text no. 4
    
5.
Martín-Navarro M, Lorenzo-Morales J, Machin RP, López-Arencibia A, García-Castellano JM, de Fuentes I, et al. Inhibition of 3-Hydroxy-3-Methylglutaryl-coenzyme a reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections. Antimicrob Agents Chemother 2013; 57(1): 375-381.  Back to cited text no. 5
    
6.
Martín-Navarro CM, López-Arencibia A, Arnalich-Montiel F, Valladares B, Piñero JE, Lorenzo-Morales J. Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba. Graefes Arch Clin Exp Ophthalmol 2013; 251(9): 2111-2117.  Back to cited text no. 6
    
7.
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532-2561.  Back to cited text no. 7
    
8.
Martín-Navarro CM, López-Arencibia A, Sifaoui I, Reyes-Batlle M, Valladares B, Martínez-Carretero E, et al. Statins and voriconazole induce programmed cell death in Acanthamoeba castellanii. Antimicrob Agents Chemother 2015; 59(5): 2817-2824.  Back to cited text no. 8
    
9.
Smith FR, Korn ED. 7-Dehydrostigmasterol and ergosterol: The major sterols of an amoeba. J Lipid Res 1968; 9(4): 405-408.  Back to cited text no. 9
    
10.
Iovieno A, Miller D, Ledee DR, Alfonso EC. Cysticidal activity of antifungals against different genotypes of Acanthamoeba. Antimicrob Agents Chemother 2014; 58(9): 5626-5628.  Back to cited text no. 10
    
11.
Mehdi H, Garg HS, Garg NK, Bhakuni DS. Sterols of Acanthamoeba culbertsoni strain A-1. Steroids 1988; 51(5): 551-558.  Back to cited text no. 11
    
12.
Arnalich-Montiel F, Martín-Navarro CM, Alió JL, López-Vélez R, Martínez-Carretero E, Valladares B, et al. Successful monitoring and treatment of intraocular dissemination of Acanthamoeba. Arch Ophthalmol 2012; 130(11): 1474-1475.  Back to cited text no. 12
    
13.
Schiller DS, Fung HB. Posaconazole: An extended-spectrum triazole antifungal agent. Clin Ther 2007; 29(9): 1862-1886.  Back to cited text no. 13
    
14.
Oliva S, Jantz M, Tiernan R, Cook DL, Judson MA. Successful treatment of widely disseminated acanthamoebiasis. South Med J 1999; 92: 55-57.  Back to cited text no. 14
    
15.
McBride J, Ingram PR, Henriquez FL, Roberts CW. Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba. J Clin Microbiol 2005; 43(2): 629-634.  Back to cited text no. 15
    
16.
Martín-Navarro CM, Lorenzo-Morales J, Cabrera-Serra MG, Rancel F, Coronado-Alvarez NM, Pinero JE, et al. The potential pathogenicity of chlorhexidine-sensitive Acanthamoeba strains isolated from contact lens cases from asymptomatic individuals in Tenerife, Canary Islands, Spain. J Med Microbiol 2008; 57(11): 1399-1404.  Back to cited text no. 16
    
17.
Lorenzo-Morales J, Kliescikova J, Martinez-Carretero E, De Pablos LM, Profotova B, Nohynkova E, et al. Glycogen phosphorylase in Acanthamoeba spp.: Determining the role of the enzyme during the encystment process using RNA interference. Eukaryotic cell 2008; 7(3): 509-517.  Back to cited text no. 17
    
18.
Martín-Navarro CM, López-Arencibia A, Sifaoui I, Reyes-Batlle M, Fouque E, Osuna A, et al. Amoebicidal activity of caffeine and maslinic acid by the induction of programmed cell death in Acanthamoeba. Antimicrob Agents Chemother 2017; 61(6): e02660-e02616.  Back to cited text no. 18
    
19.
Kulsoom H, Baig AM, Siddiqui R, Khan NA. Combined drug therapy in the management of granulomatous amoebic encephalitis due to Acanthamoeba spp., and Balamuthia mandrillaris. Exp Parasitol 2014; 145: S115-S120.  Back to cited text no. 19
    
20.
Montalvetti A, Javier PA, Hurtado R, Ruiz-Pérez LM, González-Pacanowska D. Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase. Biochem J 2000; 349(1): 27-34.  Back to cited text no. 20
    
21.
Ishibashi Y, Matsumoto Y, Kabata T, Watanabe R, Hommura S, Yasuraoka K, et al. Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis. Am J Ophthalmol 1990; 109(2): 121-126.  Back to cited text no. 21
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  2. Materials and...
  In this article
Abstract
1. Introduction
3. Results
4. Discussion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed73    
    Printed7    
    Emailed0    
    PDF Downloaded33    
    Comments [Add]    

Recommend this journal